Is HER2 overexpression sufficient for optimal response to Pertuzumab?

Med Oncol. 2012 Dec;29(4):2565-6. doi: 10.1007/s12032-012-0183-2. Epub 2012 Feb 16.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy*
  • Female
  • Humans
  • Receptor, ErbB-2 / analysis
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Receptor, ErbB-3 / analysis

Substances

  • Antibodies, Monoclonal, Humanized
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Receptor, ErbB-3
  • pertuzumab